31 Mar 2022
Assets17.74
Total Income22.58
Profit After Tax0.08
NET Worth3.08
Total Borrowing7.61
Open 14th May 2025 · Close 16th May 2025 · Listing 21st May 2025
Accretion Pharmaceuticals is a SME IPO with an issue size of ₹29.75 crore, proposed for listing on NSE SME. The offer opens on 14th May 2025 and closes on 16th May 2025. The issue structure includes a fresh issue of ₹28.26 crore.
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 1200 | ₹121,200 |
| Object | Amount |
|---|---|
| Capital expenditure towards purchase of new equipment/ machineries, etc. | ₹2.70 Cr |
| Capital expenditure towards upgradation of existing manufacturing facility | ₹4.66 Cr |
| Repayment/prepayme nt of certain borrowings availed by the Company | ₹0.99 Cr |
| Funding working capital requirements of the Company | ₹14.68 Cr |
| General Corporate Purposes | ₹4.43 Cr |
| Issue Expenses | ₹2.30 Cr |
| Total | ₹29.75 Cr |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt / Equity | 2.52% |
| RoNW | 72.47% |
| PAT Margin | 11.51% |
| Price to Book Value | 7.55 |
| Expense | Amount |
|---|---|
| Capital expenditure towards purchase of new equipment/ machineries, etc. | ₹2.70 Cr |
| Capital expenditure towards upgradation of existing manufacturing facility | ₹4.66 Cr |
| Repayment/prepayme nt of certain borrowings availed by the Company | ₹0.99 Cr |
| Funding working capital requirements of the Company | ₹14.68 Cr |
| General Corporate Purposes | ₹4.43 Cr |
| Issue Expenses | ₹2.30 Cr |
| Total | ₹29.75 Cr |